Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

Primary Recommendation

• The National Comprehensive Cancer Network recommends encorafenib plus cetuximab as the optimal second-line therapy for patients with BRAF V600E-mutant metastatic colorectal cancer who cannot tolerate fluoropyrimidine-based chemotherapy 1, 2
• Encorafenib plus cetuximab is specifically indicated for previously treated BRAF V600E-mutant metastatic colorectal cancer, providing a chemotherapy-free targeted option 3, 4
• This combination can be used in the second-line setting with Level I, Grade A evidence 2, 5

Molecular Testing

• The National Comprehensive Cancer Network recommends confirming BRAF V600E mutation status on tumor tissue using an FDA-approved test or CLIA-approved facility before initiating BRAF-targeted therapy 1, 3
• Verify RAS wild-type status to ensure appropriateness of cetuximab 1, 8, 2

Alternative Considerations

• If encorafenib plus cetuximab is not accessible, FOLFIRI without bevacizumab represents the next best option, though it still contains 5-FU 7, 8, 2
• Infusional 5-FU may be better tolerated than capecitabine in partial DYPD deficiency 7

Avoiding Common Pitfalls

• Do not use single-agent capecitabine as salvage therapy after fluoropyrimidine failure—this is ineffective and not recommended 7, 6
• Do not continue bevacizumab after progression or intolerance—there are insufficient data to support this practice 6
• Do not combine anti-VEGF and anti-EGFR antibodies—this increases toxicity without benefit 8, 6